Kawczak, P.; BÄ…czek, T.
Precision Medicine in Non-Hodgkin Lymphoma: Advances in BTK Inhibition, CD30-Directed Antibody–Drug Conjugates, and HDAC-Mediated Epigenetic Therapy with Pirtobrutinib, Brentuximab Vedotin, and Belinostat. J. Clin. Med. 2026, 15, 4425.
https://doi.org/10.3390/jcm15124425
AMA Style
Kawczak P, BÄ…czek T.
Precision Medicine in Non-Hodgkin Lymphoma: Advances in BTK Inhibition, CD30-Directed Antibody–Drug Conjugates, and HDAC-Mediated Epigenetic Therapy with Pirtobrutinib, Brentuximab Vedotin, and Belinostat. Journal of Clinical Medicine. 2026; 15(12):4425.
https://doi.org/10.3390/jcm15124425
Chicago/Turabian Style
Kawczak, Piotr, and Tomasz BÄ…czek.
2026. "Precision Medicine in Non-Hodgkin Lymphoma: Advances in BTK Inhibition, CD30-Directed Antibody–Drug Conjugates, and HDAC-Mediated Epigenetic Therapy with Pirtobrutinib, Brentuximab Vedotin, and Belinostat" Journal of Clinical Medicine 15, no. 12: 4425.
https://doi.org/10.3390/jcm15124425
APA Style
Kawczak, P., & BÄ…czek, T.
(2026). Precision Medicine in Non-Hodgkin Lymphoma: Advances in BTK Inhibition, CD30-Directed Antibody–Drug Conjugates, and HDAC-Mediated Epigenetic Therapy with Pirtobrutinib, Brentuximab Vedotin, and Belinostat. Journal of Clinical Medicine, 15(12), 4425.
https://doi.org/10.3390/jcm15124425